Web Results



Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I ...

Miglustat for treatment of Niemann-Pick C disease: a ... - NCBI


Lancet Neurol. 2007 Sep;6(9):765-72. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Patterson MC(1), Vecchio D, Prady H, ...

Zavesca - Actelion


The usual dose of Zavesca® in adult NP-C patients was 200 mg miglustat three times a day, and was adjusted according to body surface area in pediatric NP-C ...

Zavesca (Miglustat): Side Effects, Interactions, Warning, Dosage ...


Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first ...

Zavesca, INN- Miglustat - European Medicines Agency - Europa.eu


Each capsule contains 100 mg miglustat. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM. Hard capsule. White capsules with “OGT ...

Zavesca, INN- Miglustat - European Medicines Agency


Miglustat reduces the biosynthesis of glucosylceramide from ceramide ... Zavesca contains 100 mg of miglustat as active ingredient and it is presented in the ...

Zavesca (miglustat) 100 mg hard capsules - Summary of Product ...


Oct 20, 2015 ... Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SPC) by Actelion Pharmaceuticals UK Ltd.

Evaluation of miglustat as maintenance therapy after enzyme ...


Dec 27, 2012 ... Miglustat (Zavesca®; Actelion Pharmaceuticals) is an orally active iminosugar which reversibly inhibits UDP-glucosylceramide synthase – the ...

Miglustat therapy in the French cohort of paediatric patients with ...


Jun 7, 2012 ... Miglustat can improve or stabilize neurological manifestations in paediatric patients with the late-infantile and juvenile-onset forms of NP-C.

N-Butyldeoxynojirimycin film (dried in situ) | Sigma-Aldrich


film (dried in situ). Synonym: Miglustat, NB-DNJ. SDS. CAS Number 72599-27-0. Empirical Formula (Hill Notation) C10H21NO4. Molecular Weight 219.28.

More Info

DrugBank: Miglustat


Miglustat is marketed under the trade name Zavesca. Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C) .

Miglustat: MedlinePlus Drug Information


Apr 15, 2016 ... Miglustat: learn about side effects, dosage, special precautions, and more on MedlinePlus.

Miglustat: Indications, Side Effects, Warnings - Drugs.com


Easy to read patient leaflet for miglustat. Includes indications, proper use, special instructions, precautions, and possible side effects.